Foley Partner David Rosen was quoted in an article that appeared in Bloomberg News on October 27, 2011 titled “FDA tightens standards to prove generics can be swapped.” Rosen discusses in-progress FDA guidelines that will impose tighter standards for generic drug makers. He states that the guidelines will potentially require companies conducting generic equivalence studies to recruit nearly twice as many people for testing, adding that a new equivalency study would require several months to test generic products against the original versions.
People
Related News
16 May 2025
In the News
Foley's East Coast Litigation Additions Highlighted in Legal Press
Foley & Lardner LLP partners Kenneth Breen, Phara Guberman, and Joseph Dowdy are featured across legal press for their recent move to the firm.
16 May 2025
In the News
Foley Attorneys Assess AI Use in Clinical Trials
Foley & Lardner LLP partners Monica Chmielewski and Kyle Faget shared insights on the growing adoption of artificial intelligence in clinical trials in the Clinical Trials Arena article, "Are regulators keeping pace with AI adoption in clinical trials?"
15 May 2025
In the News
Grace Fucci Publishes on Sustainability in Luxury Fashion
Foley & Lardner LLP associate Grace Fucci explores the intersection of luxury fashion and sustainability in The Global Legal Post article, "Can luxury fashion houses join the sustainability discussion?"